This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
Apax/Warburg Pincus/Canadian Pension consortium makes £3.4bn cash offer for Inmarsat ($7.09 + 12c final dividend). Currently worth £2.6bn or 555p per share; a 9.6% premium to Friday’s close.
Sports Direct confirms it offered to buy Magasin du Nord from Debenhams; offered more than fair value, but received no response or valuation info to suggest offer was too low. Says House of Fraser not a competitor of Debenhams; Had dealings with advisory group, but lack of board engagement.
Pennon FY performance in-line. Doubles provision again Interserve receivables to £16m; still subject to revision. Secured £680m financing this year. South West Water 2020-2025 business plan “fast tracked” by Ofwat. Return on Regulated Equity on-track to outperform (11.8% cumulative rate).
AstraZeneca’s Forxiga oral treatment for Type-1 diabetes approved by European Commission. Drug still under review in US and Japan.
Rio Tinto has suspended some Robe Valley iron ore mining and Pilbara rail operations as cyclone hits Australia. This follows last week’s news clearing ships from ports ahead of time.
(Sources: Company newswires, Bloomberg, CNBC, FT, Reuters, Wall Street Journal)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| SMITHS GROUP | SMIN | -0.4% | 4.5% | -0.4% |
| EASYJET | EZJ | -4.7% | -1.9% | -5.8% |
| RPC | RPC | -0.2% | 0.5% | -0.6% |
| G4S | GFS | -3.1% | 0.4% | -3.2% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.
Prepared by Michael van Dulken, Head of Research